On September 13, 2022, "Shengbai Oral Liquid Bone Marrow Suppression Summit Forum • Shandong Station" hosted by Hubei Mengyang Pharmaceutical was held in the cloud.

The meeting was chaired by Professor Ma Xuezhen from Qingdao Central Hospital and Professor Wan Haitao from Qingdao Central Hospital. Prof. Zhao Kaihua, Prof. Song Haiping, Prof. Liu Shichao, Prof. Zhu Chao and Prof. Liu Yuanyuan from Qingdao Central Hospital were invited to the conference. Professor Liu Hongxun and Professor Han Minghui, West Coast Central Hospital; Professor Wang Wenhui, Professor Zhang Jianyou, Weifang People's Hospital; Professor Zhang Shixing from the Second People's Hospital of Weifang and many other experts gathered in the cloud to discuss the pathogenesis of myelopathic suppression, the mechanism of action and clinical effectiveness of Shengbai Oral liquid in the treatment of myelopathic suppression, which is a common adverse reaction in tumor diagnosis and treatment. The conference gathered many experts in the field of malignant tumor diagnosis and treatment, a strong academic atmosphere, and won multiple praise.

At the meeting, Professor Wang Wenhui from Weifang People's Hospital gave a detailed explanation on the pathogenesis of ---- myelosuppression, a common adverse reaction in the diagnosis and treatment of malignant tumors. Professor Wang Wenhui said that Shengbai oral liquid can not only increase white blood cells but also protect bone marrow hematopoietic stem cells. It can restore the normal hematopoietic function of bone marrow and effectively treat leukopenia caused by radiotherapy and chemotherapy.

Next, Professor Zhao Kaihua from Qingdao Central Hospital shared the mechanism of action and research progress of Shengbai Oral Liquid. Professor Zhao Kaihua made a detailed explanation on the mechanism of action of Shengbai Oral liquid in terms of bone marrow suppression based on modern pharmacological research results. Through the interpretation of the product prescription and how to apply Shengbai oral liquid according to the treatment course of radiotherapy and chemotherapy to achieve satisfactory curative effect made wonderful share. Let the participating experts deeply understand the effectiveness and safety of the product. The panelists also made wonderful discussions on the topics shared by Professor Wang Wenhui and Professor Zhao Kaihua.

In case sharing, Professor Zhang Jianyou from Weifang People's Hospital and Professor Liu Yuanyuan from Qingdao Central Hospital shared typical effective cases of Shengbai Oral Liquid in the prevention and treatment of myelosuppression caused by chemotherapy. Through the sharing of typical cases and comments of guests, it was concluded that prophylactic treatment before chemoradiotherapy, concurrent chemoradiotherapy, and the use of Shengbai oral liquid after chemoradiotherapy can effectively reduce or improve the level of white blood cells, and continuous medication has a significant effect. To ensure the smooth progress of chemoradiotherapy, improve the level of white blood cells can also improve the symptoms of cancer fatigue.

At the end of the conference, Professor Ma Xuezhen from Qingdao Central Hospital made a summary of the overall conference. Professor Ma Xuezhen said that in the course of conventional myelosuppression therapy, leukocytes were increased while adverse reactions occurred. Shengbai Oral liquid not only promotes white blood cells but also improves the symptoms of cancer-induced fatigue, which plays a unique role in the treatment of bone marrow suppression.

This conference was a complete success. The conference gathered many experts in the field of cancer, showing us an academic feast, highlighting the effectiveness and safety of Birth White oral liquid in clinical application. Mengyang Pharmaceutical will continue to make efforts to improve the standardization of diagnosis and treatment of malignant tumors, reduce the incidence of toxic and side effects of tumor-related treatment, improve the quality of life of patients, and ensure medical safety.